OFI, established in 1946, is headquartered in Bergamo (Lombardy). Its core business is the formulation and manufacturing of food supplements, dermo-cosmetics and medical devices, as a CDMO (Contract Development Manufacturing Organization) for 90% of its revenues, and 10% for its own brands. OFI is renowned for the high-end quality of its products, the company’s innovation and R&D skills, the depth of its product portfolio, and for its attention to regulatory issues. OFI holds more than 20,000 proprietary formulas, develops approximately 400 new products per year and sells in over 60 countries globally.

In 2020, Alto Capital IV sold its stake in OFI to Farmaceutici Procemsa, a company involved in food supplements, probiotics, dermo-cosmetics and medical devices. Farmaceutici Procemsa is controlled by the private equity fund Investindustrial, and OFI’s acquisition is a strategic step to the creation of a leader in the CDMO sphere.

In December 2020, Alto Capital IV sold its stake in OFI to Procemsa S.p.A., a company operating in the nutraceutical sector and controlled by the financial investor Investindustrial.